Editas Medicine, Inc. (EDIT) Guggenheim 6th Annual Biotechnology Conference (Transcript)


Editas Medicine, Inc. (NASDAQ:EDIT) Guggenheim 6th Annual Biotechnology Conference February 7, 2024 9:30 AM ET

Company Participants

Gilmore O’Neill – President and CEO

Conference Call Participants

Debjit Chattopadhyay – Guggenheim

Debjit Chattopadhyay

Good morning. Thank you for joining the Guggenheim Securities Healthcare team at our 6th Annual Conference. I’m Debjit and joining us from Editas Medicine is its President and CEO, Gilmore O’Neill.

Thank you so much for your time Gilmore. And if we could start off with a very quick overview of Editas.

Gilmore O’Neill

Sure. Good morning and thanks very much Debjit. Great to be here. Editas is a clinical stage company, specializing in programmable CRISPR mediated gene editing, our lead program is a reni-cel, a cell based edited therapy for the treatment of hemoglobinopathies encompassing sickle cell disease and beta thalassemia.

And I think the real key interesting thing about Editas is that we are actually actively moving through a transition from what was a technology platform company to a commercial therapeutics company with three key strategic pillars.

The first being to drive our reni-cel asset to BLA and commercialization and I’m sure we’ll talk a little bit more about that later. Basically to refocus and move the Company to a concentration on the development of in vivo therapeutics, which have the potential to truly unlock the real promise of genome editing.

And then finally, to really ramp up as we have over the past year our business development activity both through bringing in or partnering on enabling technologies to realize our in vivo editing vision as well as and very importantly to exploit the IP that we have, essentially to generate an additional non dilutive source of capital to enable us to realize our vision.

Question-and-Answer Session

Q – Debjit Chattopadhyay

So you took over June



Source link

Scroll to Top